Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$363.28
-0.3%
$337.61
$130.50
$382.54
$10.74B0.5563,927 shs355,895 shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$327.21
-1.0%
$293.14
$253.95
$385.22
$36.26B0.49374,131 shs189,268 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$32.87
-2.9%
$32.48
$10.90
$37.00
$24.34B1.114.39 million shs4.82 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.55
+9.1%
$33.19
$14.99
$37.35
$36.41B0.864.54 million shs17.76 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-0.26%+7.86%-3.93%+38.52%+138.87%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-0.98%+2.28%+12.83%+10.82%+7.02%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-2.87%-5.84%-5.36%+15.21%+187.83%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+8.62%+14.45%+4.06%-1.37%+109.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$363.28
-0.3%
$337.61
$130.50
$382.54
$10.74B0.5563,927 shs355,895 shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$327.21
-1.0%
$293.14
$253.95
$385.22
$36.26B0.49374,131 shs189,268 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$32.87
-2.9%
$32.48
$10.90
$37.00
$24.34B1.114.39 million shs4.82 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.55
+9.1%
$33.19
$14.99
$37.35
$36.41B0.864.54 million shs17.76 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-0.26%+7.86%-3.93%+38.52%+138.87%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-0.98%+2.28%+12.83%+10.82%+7.02%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-2.87%-5.84%-5.36%+15.21%+187.83%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+8.62%+14.45%+4.06%-1.37%+109.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.83
Moderate Buy$360.67-0.72% Downside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.88
Moderate Buy$394.0020.41% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.592.19% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.80
Moderate Buy$42.0021.56% Upside

Current Analyst Ratings Breakdown

Latest KRYS, ONC, TEVA, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Boost Price TargetOverweight$42.00 ➝ $44.00
7/27/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
UpgradeStrong-Buy
7/23/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOverweight$415.00 ➝ $425.00
7/17/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingSell (D-)
7/17/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Reiterated RatingSell (D-)
7/14/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Lower Price TargetOverweight$409.00 ➝ $403.00
7/14/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Boost Price TargetBuy$364.00 ➝ $396.00
7/13/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Reiterated RatingBuy$474.00
7/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$436.00 ➝ $451.00
7/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetBuy$413.00 ➝ $416.00
7/3/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
DowngradeStrong-BuyHold
(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M27.52$7.27 per share49.97$42.06 per share8.64
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B6.72$3.87 per share84.55$39.77 per share8.23
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M2,862.28N/AN/A$7.35 per share4.47
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.26B2.30$4.07 per share8.49$6.88 per share5.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.4848.5739.06N/A53.92%19.25%17.62%8/3/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4773.2030.84N/A8.94%12.06%6.69%8/5/2026 (Confirmed)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/6/2026 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$1.3325.9811.373.359.01%43.53%8.19%7/29/2026 (Estimated)

Latest KRYS, ONC, TEVA, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q1 2027
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.33N/AN/AN/A$2.00 millionN/A
8/3/2026Q2 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.70N/AN/AN/A$121.83 millionN/A
7/29/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.08$0.02-$0.06-$0.49$4.02 billion$4.14 billion
6/30/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/A$0.02N/A-$0.49N/A$4.14 billion
5/4/2026Q1 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.45$1.83+$0.38$1.83$112.11 million$116.36 million
4/29/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.46
9.06
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.70
1.01
0.78

Institutional Ownership

CompanyInstitutional Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21029.48 million25.62 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.15 billion1.14 billionOptionable

Recent News About These Companies

Branded drugs boost Teva revenue
Teva CEO on Drug Pipeline, Direct Listing on NYSE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$363.28 -0.95 (-0.26%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$365.65 +2.37 (+0.65%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$327.21 -3.25 (-0.98%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$325.50 -1.71 (-0.52%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$32.87 -0.97 (-2.87%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$32.65 -0.22 (-0.67%)
As of 07/29/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$34.55 +2.88 (+9.09%)
Closing price 07/29/2026 03:59 PM Eastern
Extended Trading
$34.50 -0.05 (-0.14%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.